Literature DB >> 25258161

Effects of the combination of wheel running and atomoxetine on cue- and cocaine-primed reinstatement in rats selected for high or low impulsivity.

Natalie E Zlebnik1, Marilyn E Carroll.   

Abstract

BACKGROUND: Aerobic exercise and the attention-deficit/hyperactivity disorder medication, atomoxetine (ATO), are two monotherapies that have been shown to suppress reinstatement of cocaine-seeking in an animal model of relapse. The present study investigated the effects of combining wheel running and ATO versus each treatment alone on cocaine-seeking precipitated by cocaine and cocaine-paired cues in rats with differing susceptibility to drug abuse (i.e., high vs. low impulsive).
METHODS: Rats were screened for high (HiI) or low impulsivity (LoI) based on their performance on a delay-discounting task and then trained to self-administer cocaine (0.4 mg/kg/inf) for 10 days. Following 14 days of extinction, both groups were tested for reinstatement of cocaine-seeking precipitated by cocaine or cocaine-paired cues in the presence of concurrent running wheel access (W), pretreatment with ATO, or both (W+ATO).
RESULTS: HiI rats acquired cocaine self-administration more quickly than LoI rats. While both individual treatments and W+ATO significantly attenuated cue-induced cocaine seeking in HiI and LoI rats, only W+ATO was effective in reducing cocaine-induced reinstatement compared with vehicle treatment. There were dose-dependent and phenotype-specific effects of ATO with HiI rats responsive to the low but not high ATO dose. Floor effects of ATO and W on cue-induced reinstatement prevented the assessment of combined treatment effects.
CONCLUSIONS: These findings demonstrated greater attenuation of cue- versus cocaine-induced reinstatement by ATO and W alone and recapitulate impulsivity phenotype differences in both acquisition of cocaine self-administration and receptivity to treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25258161      PMCID: PMC4339407          DOI: 10.1007/s00213-014-3744-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  89 in total

Review 1.  Choosing a behavioral therapy platform for pharmacotherapy of substance users.

Authors:  Kathleen M Carroll; Thomas R Kosten; Bruce J Rounsaville
Journal:  Drug Alcohol Depend       Date:  2004-08-16       Impact factor: 4.492

2.  Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.

Authors:  Barry Holzer; Vasco Lopes; Robert Lehman
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-08       Impact factor: 2.576

3.  Chronic atomoxetine treatment during adolescence decreases impulsive choice, but not impulsive action, in adult rats and alters markers of synaptic plasticity in the orbitofrontal cortex.

Authors:  Haosheng Sun; Paul J Cocker; Fiona D Zeeb; Catharine A Winstanley
Journal:  Psychopharmacology (Berl)       Date:  2011-08-02       Impact factor: 4.530

4.  American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise.

Authors:  Carol Ewing Garber; Bryan Blissmer; Michael R Deschenes; Barry A Franklin; Michael J Lamonte; I-Min Lee; David C Nieman; David P Swain
Journal:  Med Sci Sports Exerc       Date:  2011-07       Impact factor: 5.411

5.  Impulsivity (delay discounting) as a predictor of acquisition of IV cocaine self-administration in female rats.

Authors:  Jennifer L Perry; Erin B Larson; Jonathan P German; Gregory J Madden; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

Review 6.  Norepinephrine and stimulant addiction.

Authors:  Mehmet Sofuoglu; R Andrew Sewell
Journal:  Addict Biol       Date:  2008-09-22       Impact factor: 4.280

Review 7.  Impulsivity as a determinant and consequence of drug use: a review of underlying processes.

Authors:  Harriet de Wit
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

8.  Exercise-related activities are associated with positive outcome in contingency management treatment for substance use disorders.

Authors:  Jeremiah Weinstock; Danielle Barry; Nancy M Petry
Journal:  Addict Behav       Date:  2008-04-06       Impact factor: 3.913

9.  Exercise as a potential treatment for drug abuse: evidence from preclinical studies.

Authors:  Mark A Smith; Wendy J Lynch
Journal:  Front Psychiatry       Date:  2012-01-12       Impact factor: 4.157

10.  The relationship between impulsive choice and impulsive action: a cross-species translational study.

Authors:  Nienke Broos; Lianne Schmaal; Joost Wiskerke; Lennard Kostelijk; Thomas Lam; Nicky Stoop; Lonneke Weierink; Jannemieke Ham; Eco J C de Geus; Anton N M Schoffelmeer; Wim van den Brink; Dick J Veltman; Taco J de Vries; Tommy Pattij; Anna E Goudriaan
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

View more
  19 in total

1.  Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects.

Authors:  Elise E DeVito; Aryeh I Herman; Noah S Konkus; Huiping Zhang; Mehmet Sofuoglu
Journal:  Pharmacol Biochem Behav       Date:  2017-07-14       Impact factor: 3.533

2.  Prevention of the incubation of cocaine seeking by aerobic exercise in female rats.

Authors:  Natalie E Zlebnik; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2015-07-11       Impact factor: 4.530

3.  Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.

Authors:  Britahny M Baskin; Bríd Á Nic Dhonnchadha; Linda P Dwoskin; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2017-07-20       Impact factor: 4.530

4.  Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists.

Authors:  Guy A Higgins; Leo B Silenieks; Everett B Altherr; Cam MacMillan; Paul J Fletcher; Wayne E Pratt
Journal:  Psychopharmacology (Berl)       Date:  2016-05-30       Impact factor: 4.530

5.  Sex differences in the reduction of impulsive choice (delay discounting) for cocaine in rats with atomoxetine and progesterone.

Authors:  John R Smethells; Natashia L Swalve; Lynn E Eberly; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2016-06-20       Impact factor: 4.530

Review 6.  How to study sex differences in addiction using animal models.

Authors:  Marilyn E Carroll; Wendy J Lynch
Journal:  Addict Biol       Date:  2016-06-26       Impact factor: 4.280

7.  Sex differences in the effects of a combined behavioral and pharmacological treatment strategy for cocaine relapse prevention in an animal model of cue exposure therapy.

Authors:  Kathleen M Kantak; Jamie M Gauthier; Elon Mathieson; Eudokia Knyazhanskaya; Pedro Rodriguez-Echemendia; Heng-Ye Man
Journal:  Behav Brain Res       Date:  2020-08-02       Impact factor: 3.332

8.  Sex differences in attenuation of nicotine reinstatement after individual and combined treatments of progesterone and varenicline.

Authors:  Natashia Swalve; John R Smethells; Marilyn E Carroll
Journal:  Behav Brain Res       Date:  2016-04-21       Impact factor: 3.332

9.  Effects of voluntary exercise and sex on multiply-triggered heroin reinstatement in male and female rats.

Authors:  J R Smethells; A Greer; B Dougen; M E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2019-11-11       Impact factor: 4.530

10.  Sex differences in reinstatement of cocaine-seeking with combination treatments of progesterone and atomoxetine.

Authors:  Natashia Swalve; John R Smethells; Natalie E Zlebnik; Marilyn E Carroll
Journal:  Pharmacol Biochem Behav       Date:  2016-03-19       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.